Cargando…

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined chang...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wolfe, T. J., Eggers, S., Barker, A. K., Kates, A. E., Dill-McFarland, K. A., Suen, G., Safdar, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161886/
https://www.ncbi.nlm.nih.gov/pubmed/30265691
http://dx.doi.org/10.1371/journal.pone.0204253
_version_ 1783359068420702208
author De Wolfe, T. J.
Eggers, S.
Barker, A. K.
Kates, A. E.
Dill-McFarland, K. A.
Suen, G.
Safdar, N.
author_facet De Wolfe, T. J.
Eggers, S.
Barker, A. K.
Kates, A. E.
Dill-McFarland, K. A.
Suen, G.
Safdar, N.
author_sort De Wolfe, T. J.
collection PubMed
description Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10(10) CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
format Online
Article
Text
id pubmed-6161886
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-61618862018-10-19 Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection De Wolfe, T. J. Eggers, S. Barker, A. K. Kates, A. E. Dill-McFarland, K. A. Suen, G. Safdar, N. PLoS One Research Article Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10(10) CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI. Public Library of Science 2018-09-28 /pmc/articles/PMC6161886/ /pubmed/30265691 http://dx.doi.org/10.1371/journal.pone.0204253 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
De Wolfe, T. J.
Eggers, S.
Barker, A. K.
Kates, A. E.
Dill-McFarland, K. A.
Suen, G.
Safdar, N.
Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title_full Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title_fullStr Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title_full_unstemmed Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title_short Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
title_sort oral probiotic combination of lactobacillus and bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for clostridium difficile infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161886/
https://www.ncbi.nlm.nih.gov/pubmed/30265691
http://dx.doi.org/10.1371/journal.pone.0204253
work_keys_str_mv AT dewolfetj oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT eggerss oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT barkerak oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT katesae oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT dillmcfarlandka oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT sueng oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection
AT safdarn oralprobioticcombinationoflactobacillusandbifidobacteriumaltersthegastrointestinalmicrobiotaduringantibiotictreatmentforclostridiumdifficileinfection